Clinical Trials Logo

Clinical Trial Summary

This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptoms were present for up to 14 days prior to recanalization. The goal of the study is to see if local anti-inflammation helps prevent re-thrombosis of the blood vessel and improvement in symptoms for up to 24 months after the initial DVT recanalization procedure.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04862468
Study type Interventional
Source Mercator MedSystems, Inc.
Status Not yet recruiting
Phase Phase 2
Start date June 1, 2021
Completion date August 1, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03804125 - A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
Not yet recruiting NCT04731558 - Pre- vs Postoperative Thromboprophylaxis for Liver Resection Phase 4
Not yet recruiting NCT03812835 - A Study of Adverse Events and Suspected Adverse Drug Reactions of Patients Under Treatment of Apixaban for Venous Thomboembolism (VTE) Treatment